
    
      Capecitabine (Xeloda Â®) is currently the most biologically active oral fluoropyrimidine drug,
      and is widely used as first-line and second-line rescue therapy for advanced breast cancer
      ,third-generation aromatase inhibitors (AI) is the preferred adjuvant endocrine therapy for
      Postmenopausal hormone-sensitive breast cancer. Study showed that AI combined with metronomic
      chemotherapy could improve the objective response and clinical benefit in neoadjuvant
      therapy.
    
  